Catalog No.
Product Name
Application
Product Information
Citations
-
Topoisomerase II Inhibitor
Razoxane is a topoisomerase II inhibitor known for its antiangiogenic properties. It exhibits significant antineoplastic and antimetastatic activities, making it a valuable tool in cancer research. Razoxane is particularly relevant for studies focusing on renal cell carcinoma (RCC), lung cancer, and melanoma, offering insights into tumor growth and metastasis mechanisms. -
TopI Inhibitor
20-O-Acetylcamptothecin is a potent inhibitor of Topoisomerase I, derived from the natural alkaloid Camptothecin. This compound exhibits significant antitumor activity by stabilizing the DNA-topoisomerase complex, leading to DNA strand breaks and subsequent cell death. It is widely utilized in cancer research to elucidate mechanisms of action and to explore therapeutic strategies targeting Topoisomerase I in various malignancies. -
Bioactive Component
1,4-Di-tert-butylbenzene is a bioactive compound known for its inhibitory effects on bacterial type II topoisomerases, specifically 4PLB and LpxC, as demonstrated in docking studies. This compound has potential applications in antibacterial research, providing a valuable tool for investigating mechanisms of resistance and developing new therapeutic strategies. Its presence in natural sources such as corn cob and green millet underscores its relevance in phytochemical studies. -
Top1 Inhibitor
meso-Tetra(4-pyridyl)porphine is a porphyrin derivative that acts as a weak inhibitor of human topoisomerase I (Top1), with an EC50 value exceeding 50 µM. This compound is of interest in tumor research, enabling investigations into the role of Top1 in cancer biology and potential therapeutic strategies. Its unique structural features make it a valuable tool for studying topoisomerase-related mechanisms in cellular processes. -
Anticancer Agent
Elinafide is an anticancer agent featuring a naphthalimide structure that targets DNA. It disrupts cellular metabolism by inserting a planar ring into the DNA double helix, leading to interactions with topoisomerase II enzymes. This mechanism results in significant cytotoxicity, with an IC50 value of 0.014 μM observed in HT-29 colorectal cancer cells. Elinafide is applicable for research on DNA-binding compounds and their therapeutic potential in oncology. -
TOP Inhibitor
PNU-142586 is an inhibitor of DNA topoisomerase 2-α (TOP2A) and DNA topoisomerase 2-β (TOP2B) that serves as a major metabolite of Linezolid. By obstructing the binding of DNA to topoisomerases and inhibiting ATP hydrolysis, PNU-142586 disrupts DNA replication and transcription, leading to antiproliferative and cytotoxic effects, including mitochondrial dysfunction. This compound is valuable for investigating Linezolid-induced hematotoxicity and elucidating its underlying molecular mechanisms. -
Topoisomerase II Inhibitor
ARN21929 is an inhibitor of Topoisomerase II, exhibiting an IC50 value of 4.5 μM. This compound demonstrates favorable kinetic and thermodynamic solubility along with metabolic stability. Although ARN21929 shows limited antiproliferative activity against A549, DU145, MCF7, HeLa, and A375 cell lines, it remains a valuable tool for exploring mechanisms of cancer biology. -
Topoisomerase I Inhibitor
CH-0793076 is a potent inhibitor of DNA topoisomerase I, exhibiting an IC50 of 2.3 μM. This hexacyclic camptothecin analog serves as both an active drug and a significant metabolite of TP300. CH-0793076 demonstrates efficacy in cells that express the breast cancer resistance protein (BCRP), making it a valuable compound for investigating resistance mechanisms in oncology research. -
Topo II inhibitor
AQ4 is a topoisomerase II inhibitor and DNA intercalator that exhibits cytotoxic activity across various human tumor cell lines. This compound interferes with DNA replication and transcription, leading to cell cycle arrest and apoptosis. It is utilized in cancer research to study the mechanisms of DNA damage and the efficacy of potential therapeutic agents. -
Topoisomerase I Inhibitor
CH-0793076 TFA is a hexacyclic camptothecin analog that functions as a potent inhibitor of DNA topoisomerase I, exhibiting an IC50 value of 2.3 μM. This compound demonstrates significant efficacy against tumor cells expressing the breast cancer resistance protein (BCRP). CH-0793076 TFA is primarily utilized in cancer research, particularly for studies focused on overcoming drug resistance in breast cancer and other malignancies where topoisomerase I plays a critical role. -
Topoisomerase I Inhibitor
Indotecan hydrochloride is a potent inhibitor of Topoisomerase I, demonstrating IC50 values of 300, 1200, and 560 nM in P388, HCT116, and MCF-7 cell lines, respectively. This indenoisoquinoline derivative functions by preventing the relaxation of supercoiled DNA, thus interfering with DNA replication and transcription processes. Indotecan hydrochloride has potential applications in cancer research and is also relevant in the study of visceral leishmaniasis. -
Topoisomerase Inhibitor
Silatecan is a topoisomerase I inhibitor that functions by interfering with DNA replication and transcription processes. As an analogue of Camptothecin, Silatecan exhibits enhanced stability and lipophilicity, making it a valuable agent for cancer research. Its notable antitumor properties and radiosensitizing effects contribute to its potential applications in oncology studies. -
DNA Topoisomerases I/II Inhibitor
Batracylin (NSC320846) is a potent inhibitor of DNA Topoisomerases I and II. It exhibits significant cytotoxic and antiproliferative effects, leading to the induction of DNA breaks in cellular systems. Batracylin is valuable for research applications focused on cancer biology, specifically in studies exploring the mechanisms of DNA damage and repair. -
Antitumor Agent
Sabarubicin is a doxorubicin disaccharide analogue that functions as an antitumor agent primarily through the inhibition of topoisomerase II. It demonstrates enhanced efficacy compared to doxorubicin, promoting DNA fragmentation at lower intracellular concentrations. This compound is valuable for researching mechanisms of cancer cell proliferation and apoptosis. -
Topoisomerase I Inhibitor
Diflomotecan is a potent inhibitor of topoisomerase I, exhibiting strong oral bioavailability. It demonstrates enhanced plasma stability and superior preclinical anti-tumor activity compared to established compounds. This makes Diflomotecan a valuable tool for cancer research and therapeutic development targeting topoisomerase I pathways. -
SN-38 Derivative
CL2-MMT-SN38 is a derivative of SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11). This compound exhibits potent anticancer activity by inducing DNA damage through the stabilization of the topoisomerase-DNA complex. Its unique structure makes it valuable for research applications focused on cancer therapeutics and the mechanistic understanding of topoisomerase inhibition. -
Antitumor Agent
Antitumor agent-63 is a 20 (S)-O-linked camptothecin (CPT) glycoconjugate predominantly targeting tumor cells while exhibiting minimal toxicity to normal cells. This compound demonstrates significant stability and presents very weak direct inhibition of topoisomerase I (Topo I). Its unique profile makes it a valuable candidate for research applications in cancer therapeutics and drug development. -
opoisomerase I Inhibitor T
Simmitecan hydrochloride is a potent inhibitor of topoisomerase I, derived from the 9-substituted lipophilic Camptothecin framework. This compound exhibits significant anticancer activity, making it a valuable reagent for cancer research. Simmitecan hydrochloride is utilized in studies focused on exploring mechanisms of tumor resistance and developing novel therapeutic strategies. -
Topoisomerase Inhibitor
CP-84364 is a potent topoisomerase I inhibitor that displays a dose-dependent inhibitory effect with an IC50 of 7.25 μg/mL. This compound shows significant antiproliferative and anticancer activities, making it valuable for cancer research and evaluating therapeutic strategies targeting topoisomerase I. Its ability to hinder cellular proliferation positions CP-84364 as a useful tool in the study of cancer biology and drug development. -
Doxorubicin Prodrug
SDOX is a doxorubicin prodrug designed to release the active compound doxorubicin in response to elevated levels of glutathione (GSH) found in tumor cells. This targeted mechanism minimizes adverse effects on healthy tissues while maintaining the therapeutic efficacy of doxorubicin. SDOX is suitable for research applications focused on cancer treatment and overcoming multidrug resistance. -
Anticancer Agent
Anticancer Agent 215 is a Camptothecin derivative that inhibits topoisomerase I activity. It demonstrates potent antiproliferative effects, with IC50 values of 5.2 nM in MCF-7 breast cancer cells and 8.2 nM in MDA-MB-231 cells. This compound is suited for cancer research applications, particularly in studies aimed at evaluating topoisomerase inhibition and exploring novel therapeutic strategies against breast cancer. -
Camptothecin Enantiomer
(R)-Camptothecin is the enantiomer of Camptothecin (CPT), specifically designed to lack inhibitory activity against DNA topoisomerase I (Top1). Due to its inability to hinder the DNA religation process, (R)-Camptothecin does not exhibit the cytotoxic properties characteristic of its active counterpart. This compound is primarily utilized in research applications focused on elucidating the mechanisms of action of camptothecin derivatives and understanding their pharmacological profiles. -
Topoisomerase II Inhibitor
Bimolane, a potent inhibitor of human topoisomerase II, serves as an important tool in cancer research and therapy. This compound exhibits anti-neoplastic properties and has been investigated for its potential applications in psoriasis research. Additionally, Bimolane has demonstrated leukemogenic activity and the ability to induce various chromosomal aberrations in human lymphocytes, making it valuable for studies on genomic instability. -
TOP3B Inhibitor
TOP3B-IN-1 is a selective inhibitor of Topoisomerase IIIβ (TOP3B), disrupting the formation of TOP3B cleavage complexes (TOP3Bccs) with DNA and RNA. This compound destabilizes existing TOP3Bccs, making it valuable for investigating the role of TOP3B in cellular processes. TOP3B-IN-1 serves as a useful control in the development of new TOP3B-targeting inhibitors, allowing for enhanced understanding of this enzyme’s function in biological systems. -
Topoisomerase Inhibitor
Topoisomerase II inhibitor 1 is a selective inhibitor targeting topoisomerase IIα, a critical enzyme involved in DNA replication and cell division. This compound demonstrates potent biological activity in disrupting DNA topology, leading to the prevention of DNA strand separation. It is utilized in research applications focused on cancer biology and the development of anti-cancer therapeutics, particularly in studies examining DNA repair mechanisms and cellular proliferation. -
Anti-leukemia Compound
Moflomycin is a potent anti-leukemia compound that exhibits strong antiproliferative effects, particularly against the HL60 leukemic cell line, with an IC50 of 2.9 nM. Its mechanism involves enhancing topoisomerase II-induced DNA breaks and stimulating free radical production. Moflomycin presents valuable opportunities for research applications in leukemia treatment and drug development. -
Topoisomerase I Inhibitor
10-Nitrocamptothecin is a potent inhibitor of topoisomerase I, exhibiting an IC50 value of 0.64 μM. This compound disrupts the formation of cleavable complexes, thereby effectively inhibiting topoisomerase I activity. It is widely utilized in cancer research to explore therapeutic strategies targeting DNA replication and repair mechanisms. -
topoisomerase I/II Inhibitor
XR11576 is an orally active inhibitor of topoisomerase I and II, demonstrating significant cytotoxicity against both human and murine tumor cell lines, with IC50 values ranging from 6 to 47 nM. This compound is primarily utilized in cancer research to explore the mechanisms of DNA replication and repair, making it a valuable tool for investigations into anticancer therapies and the underlying biology of tumor cells. -
DNA Topoisomerase Inhibitor
BE-10988 is a potent DNA topoisomerase inhibitor that disrupts the normal function of this enzyme, leading to the formation of stabilized enzyme-DNA complexes. This compound effectively inhibits the growth of Doxorubicin- and vincristine-resistant P388 mouse leukemia cell lines, indicating its potential utility in overcoming drug resistance in cancer treatment. BE-10988 offers valuable insights for research in cancer biology and therapeutic development. -
TopoI Inhibitor
GI-149893 is a selective topoisomerase I (TopoI) inhibitor that disrupts the religation of DNA, leading to irreversible DNA damage in tumor cells. This compound demonstrates significant cytotoxic effects against various cancer cell lines, including colon carcinoma (HT-29/SW-48), breast cancer (MX-1), and prostate cancer xenografts (PC-3). GI-149893 serves as a valuable tool for cancer research, particularly in the exploration of therapeutic strategies targeting TopoI. -
Anticancer Agent
Tenifatecan is an injectable emulsion designed primarily as an anticancer agent. It consists of vitamin E and a succinate derivative, along with 7-ethyl-10-hydroxycamptothecin (SN-38), which is the active metabolite of irinotecan. Tenifatecan exhibits potent anticancer activity, making it a valuable compound for research applications in cancer therapy and drug development. -
Doxorubicin Analog
Camsirubicin is a non-cardiotoxic analog of Doxorubicin that selectively targets topoisomerase IIβ. This compound demonstrates significant anti-proliferative effects, reducing cell viability and clone formation in MDA-MB-468 breast cancer cells. Furthermore, Camsirubicin enhances the surface exposure of calreticulin (CALR) and heat shock protein 90 (HSP90). It is an effective reagent for studies focused on breast cancer biology and therapeutic strategies. -
Topoisomerase Inhibitor
S 39625 is a camptothecin ketone analogue that functions as a selective inhibitor of topoisomerase I. This compound exhibits potent activity against purified topoisomerase I and demonstrates cytotoxic effects in cancer cells. It is a valuable reagent for research applications involving cancer biology and the study of topoisomerase inhibition mechanisms. -
Topoisomerase
Ro 47-3359 is a pyrimido[1,6-a]benzimidazole compound that specifically enhances the activity of eukaryotic topoisomerase II, promoting DNA cleavage. This compound has demonstrated cytotoxic effects in Kc cells, making it a valuable tool for studying topoisomerase function and the mechanisms underlying cellular response to DNA damage. Ro 47-3359 is relevant for research applications in cancer biology and DNA repair pathways. -
DNA topoisomerase I Inhibitor
9-Chloromethyl-10-hydroxy-11-F-Camptothecin is a potent inhibitor of DNA topoisomerase I, a key enzyme involved in DNA replication and transcription. This compound exhibits significant anticancer activity by inducing DNA damage through the stabilization of the enzyme-DNA cleavable complex. It is particularly useful in cancer research for studying the mechanisms of tumor progression and therapy resistance, as well as evaluating potential chemotherapeutic strategies. -
DNA Topoisomerases I/II Inhibitor
Nectandrin B is an inhibitor of DNA topoisomerases I and II, derived from Saururus chinensis. It exhibits significant potential in cancer research by disrupting the topoisomerase activity essential for DNA replication and repair. This compound serves as a valuable tool for investigating the therapeutic mechanisms and efficacy of topoisomerase-targeted treatments in oncology. -
Topoisomerase II-Targeted Agent
CP-67804 is a quinolone derivative that targets topoisomerase II. This compound effectively enhances DNA cleavage mediated by eukaryotic topoisomerase II, showcasing its potential as an antineoplastic agent. CP-67804 is suitable for research applications focused on cancer biology and DNA topology. -
Topoisomerase II Inhibitor
Pixantrone hydrochloride is a topoisomerase II inhibitor that functions through DNA intercalation, exhibiting significant anti-tumor activity. It is a structural analog of mitoxantrone and has shown promise in preclinical and clinical studies for treating various malignancies. This compound is valuable for research applications in cancer biology, particularly in studies focused on the mechanisms of DNA damage and repair, as well as the assessment of therapeutic efficacy in oncology. -
Topoisomerase II Inhibitor
Topoisomerase II Inhibitor 4 (compound E17) targets the topoisomerase II enzyme, disrupting DNA replication and repair processes. It is characterized by its ability to induce G2/M cell cycle arrest, demonstrating significant anti-tumor activity through potent cytotoxic and anti-proliferative effects. This compound is suitable for research applications focused on cancer biology and therapeutic development. -
Topoisomerase Inhibitor
Topotecan acetate is a topoisomerase inhibitor that functions by stabilizing the topoisomerase-DNA complex during DNA replication, ultimately leading to DNA damage and cell death. This compound demonstrates potent antitumor activity, particularly in the treatment of ovarian and small cell lung cancers. Topotecan acetate is utilized in various research applications to study cellular responses to DNA damage and to evaluate potential therapeutic strategies in oncology. -
Topo IIα Inhibitor
Topoisomerase IIα-IN-2 is a potent inhibitor of topoisomerase IIα, targeting the enzyme's DNA-binding activity. It demonstrates significant antiproliferative effects against various human cancer cell lines and induces substantial DNA damage. Additionally, Topoisomerase IIα-IN-2 effectively halts cancer cell progression at the G2/M phase, making it a valuable reagent for cancer research and therapeutic investigations. -
Topo I inhibitor
Fagopyrine is a potent inhibitor of DNA topoisomerase I (Topo I), an enzyme critical for DNA relaxation and transcription processes. Its ability to intercalate into DNA makes Fagopyrine a valuable tool in cancer research, particularly in studies involving tumor dynamics and photosensitization therapies. This compound can be instrumental in understanding the role of Topo I in tumor cell proliferation and response to treatment. -
Topoisomerase Inhibitor
A 9387 is a topoisomerase inhibitor that specifically targets Tn3 Resolvase, interrupting its role in site-specific recombination between directly repeated sequences. This compound effectively inhibits the binding of resolvase to the resolution site, thereby preventing the recombination process. A 9387 is valuable for research applications in genetic recombination and molecular biology studies focused on DNA manipulation and topological changes. -
Topoisomerase I Inhibitor
β-Glu-PAB(CH2NH2)-Exatecan is a selective inhibitor of topoisomerase I. It disrupts the topoisomerase I-DNA complex, preventing DNA strand rejoining, which leads to DNA breakage and subsequent apoptosis in cancer cells. This compound is specifically designed to be activated by β-glucuronidase, which is highly expressed in the tumor microenvironment, thereby activating Exatecan and enhancing its cytotoxicity. β-Glu-PAB(CH2NH2)-Exatecan serves as a valuable tool for cancer research, particularly in exploring targeted therapies. -
Topoisomerase I Inhibitor
Topoisomerase I-IN-19 is a potent inhibitor of Topoisomerase I, a critical enzyme involved in DNA replication and transcription. This compound facilitates the study of Topoisomerase I-mediated diseases, particularly in cancer research, by allowing for the evaluation of cell growth, apoptosis, and the therapeutic potential of Topoisomerase I inhibition. Its efficacy in modulating Topoisomerase I activity makes it a valuable tool for mechanistic studies and drug development in oncology. -
Topoisomerase II Inhibitor
Topoisomerase II Inhibitor 18 is a quinoxaline derivative that selectively inhibits topoisomerase II with an IC50 of 7.5 μM. This compound effectively suppresses cell proliferation and induces G1/S phase cell cycle arrest, leading to apoptosis in PC-3 cancer cells. It demonstrates significant antitumor activity, making it a valuable tool for cancer research applications focused on topoisomerase II modulation. -
DNA Topoisomerase Inhibitor
PNU-142586 sodium is a potent inhibitor of DNA topoisomerase 2-α (TOP2A) and DNA topoisomerase 2-β (TOP2B). This compound effectively disrupts DNA replication and transcription by preventing the binding of DNA to TOP2 and inhibiting ATP hydrolysis, resulting in antiproliferative and cytotoxic effects, including mitochondrial dysfunction. PNU-142586 sodium is primarily utilized in research investigating Linezolid-induced hematotoxicity and its underlying molecular mechanisms. -
Antitumor Agent
Piroxantrone is a potent anthrapyrazole antitumor agent that primarily targets DNA topoisomerase II. It exhibits significant cytotoxic effects on cancer cells, making it a valuable compound for research in oncological studies. However, it is important to note that Piroxantrone also displays cardiotoxicity, highlighting the need for careful evaluation in therapeutic applications. -
Topoisomerase II Inhibitor
Topoisomerase II inhibitor 6 is a potent and selective inhibitor of topoisomerase II, derived from tryptanthrin. This compound demonstrates significant antiproliferative activity across various tumor cell lines and effectively halts the cell cycle of CCRF-CEM cells at the G2 phase, while inducing DNA double-strand breaks (DSBs). Its robust mechanism of action makes Topoisomerase II inhibitor 6 a valuable reagent for cancer research and therapeutic investigations. -
Topoisomerase Inhibitor
Amonafide dihydrochloride is a potent inhibitor of topoisomerase II, functioning by disrupting the enzyme's binding to DNA and subsequently halting DNA and RNA synthesis. This compound exhibits significant cytotoxicity and is capable of inducing apoptotic signaling pathways. Notably, Amonafide dihydrochloride retains its efficacy in the context of P-glycoprotein-mediated multidrug resistance, making it a valuable tool for cancer research and development of therapies targeting resistant tumors.
